TorHoerman Law Advocates for Infants in Pivotal Missouri NEC Trial Against Formula Manufacturers
TorHoerman Law Advocates for Infants in Pivotal Missouri NEC Trial Against Formula Manufacturers
ST. LOUIS, July 3, 2024 /PRNewswire/ -- TorHoerman Law is set to begin trial on July 8, 2024, in Missouri state court. The case will focus on allegations that cow milk-based baby formula is linked to necrotizing enterocolitis (NEC), a dangerous condition affecting premature infants.
2024年7月3日聖路易斯 / PRNewswire / - TorHoerman Law將於2024年7月8日在密蘇里州法院開始審判。該案將關注關於奶牛奶基嬰兒配方與壞死性腸炎（NEC）的聯繫。這是一種危及早產兒的嚴重病症。
The case, Margot Gill, on behalf of herself and her minor child R.D. v. Abbott Laboratories, et al., case number 2322-CC01251, will be heard before Judge Michael Noble in Missouri's 22nd Judicial Circuit in the City of St. Louis. The trial is part of a series of bellwether trials, with thousands of similar cases pending and another major trial scheduled in federal multi-district litigation in early 2025.
此案件名爲Margot Gill,v. Abbott Laboratories等, 案號2322-CC01251, 將在聖路易市第22巡迴審判法院Michael Noble法官主持下審理。本案是一系列標誌性訴訟案件的一部分，目前還有數千個類似案件待審理，另一起重大案件定於2025年初在聯邦多區域訴訟中審理。該案是針對Abbott Laboratories的慣常控件，與早先針對Mead Johnson & Company的案件不同。這兩家公司都曾維護其奶粉的安全。"我們相信證據將清楚地顯示這些配方與NEC之間的聯繫，並強調立即採取行動保護我們最脆弱的人群的必要性。"來自TorHoerman Law的律師Jake Plattenberger和合夥人表示。
This trial follows a prior case in Illinois where a jury awarded $60 million to a plaintiff whose premature infant tragically died from NEC after consuming cow milk-based formula.
此次審判是在伊利諾伊州的一起案件之後進行的，當時陪審團判定原告早產兒因爲飲用奶牛奶配方而不幸去世，判決原告賠償6000萬美元。
"As we prepare to present our case, we remain firmly committed to proving that the negligence of formula manufacturers has led to severe suffering and injustice for many families," said attorney Tor Hoerman. "This trial is not just about compensation, but about ensuring such tragedies are prevented in the future."
"在準備提出我們的案件時，我們始終致力於證明配方生產商的過失導致許多家庭經歷了嚴重的痛苦和不公正。這次審判不僅僅是爲了賠償，更是爲了確保未來避免這樣的悲劇發生。"來自Tor Hoerman的律師表示。
This litigation involves allegations against Abbott Laboratories, contrasting the earlier case against Mead Johnson & Company, LLC. Both companies have historically defended the safety of their formulas.
此次訴訟涉及對Abbott Laboratories的指控，與早期對Mead Johnson & Company的案件相反。這兩家公司都曾維護其奶粉的安全。
"We believe the evidence will clearly show the link between these formulas and NEC, and underscore the need for immediate action to protect our most vulnerable," said Jake Plattenberger, attorney & partner at TorHoerman Law.
"我們相信證據將清楚地顯示這些配方與NEC之間的聯繫，並強調立即採取行動保護我們最脆弱的人群的必要性。"來自TorHoerman Law的律師Jake Plattenberger和合夥人表示。
The plaintiffs are supported by attorneys from TorHoerman Law and Stranch Jennings & Garvey PLLC. Defense for Abbott Laboratories includes Winston & Strawn LLP's Chicago office, Kirkland & Ellis LLP's Chicago and Los Angeles offices, and Jones Day's Washington D.C. office, along with local Missouri counsel from HeplerBroom LLC and Thompson Coburn LLP.
原告由來自TorHoerman Law和Stranch Jennings & Garvey PLLC的律師提供支持。Abbott Laboratories的辯護律師包括溫斯頓和斯特勞恩LLP的芝加哥辦事處、柯克蘭和埃利斯LLP的芝加哥和洛杉磯辦事處、瓊斯戴的華盛頓特區辦事處以及HeplerBroom LLC和 Thompson Coburn LLP的當地律師。
The trial, expected to extend through most of July, promises to be a cornerstone case with significant implications for product liability law and neonatal care standards nationwide.
預計審判將在大部分時間內延續到7月底，將成爲具有重要意義的案件，對產品責任法和新生兒護理標準的影響將具有重大意義。
SOURCE TorHoerman Law
TorHoerman Law來源
譯文內容由第三人軟體翻譯。